Biotech company Dyno Therapeutics secured $100 Million funding

Dyno Therapeutics, a Cambridge based biotech company applying AI to gene therapy, has now secured $100 million in a Series A funding round.

Dyno Therapeutics is founded by Eric Kelsic. The biotech startup is working on advancing the CapsidMap platform,. The platform uses AI technology for the design of novel Adeno Associated Virus therapy vectors, broadening the functionality and enhancing the therapeutic impact of gene therapies being developed by its biopharmaceutical partners.

Jorge Conde, General Partner at Andreessen Horowitz, said, "Dyno’s AI-powered approach to designing gene therapy vectors has transformative potential to expand the treatment landscape for gene therapies, opening new opportunities to cure thousands of diseases for patients. Up until now, gene therapies have been stymied from treating more diseases and reaching more patients due to the limitations of naturally occurring AAV vectors. The field needs improved gene delivery and is eager to discover and adopt improved AAV vectors. Dyno directly addresses and solves this challenge."

Eric Kelsic, Ph.D., founder, and CEO of Dyno Therapeutics, said, "This Series A financing accelerates our AI-powered discovery of best-in-class capsids targeting all major organs and cell types, enabling Dyno to grow our business infrastructure and establish more partnerships to become the premier developer of gene therapy vectors. Dyno was the first to combine machine learning with data from high-throughput in vivo experiments to optimize and accelerate the design of improved capsids for gene therapy. Our CapsidMap platform brings unprecedented scale and technical sophistication to solving in vivo delivery, the key challenge for gene therapy, making therapies more effective, safe, manufacturable and capable of benefiting more patients."

Andreessen Horowitz led the latest funding round for Dyno Therapeutics. Other participating investors for the biotech company's funding round include the Obvious Ventures, GV, Casdin Capital, and Lux Capital. All the three founding investors including the CRV, KdT Ventures, and Polaris Partners, also participated in the funding round.

Post funding, Jorge Conde, the general partner at Andreessen Horowitz, will join the Dyno Therapeutics' Board of Directors team.

Dyno Therapeutics, as of now, has plans to use the new funds to expand its CapsidMap platform. The new funding will accelerate building Dyno Therapeutics' CapsidMap platform to design improved vectors targeting muscle, liver, eye, and central nervous system disease, as well as growing into new areas of heart, lungs, and kidney disease.

The biotech company will also use the new funds to support its multiple partnership efforts with the gene therapy biopharmaceutical companies, notes the announcement.